Market Closed - Euronext Paris 08:54:19 2024-04-17 am EDT 5-day change 1st Jan Change
0.37 EUR -0.54% Intraday chart for Theraclion +1.09% -4.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Inner Mongolia Furui Medical Science Co., Ltd. agreed to acquire an additional 27.78% stake in Theraclion Medical Equipment Co., Ltd. from Theraclion SA for ?1 CI
Theraclion SA announced that it has received €8.353961 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Theraclion Names CEO MT
Theraclion Appoints Martin Deterre as CEO CI
Theraclion SA announced that it expects to receive €7 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Theraclion SA announced that it expects to receive ?12.649999 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Global markets live: HSBC, Logitech, Uber, IBM, BP... Our Logo
Theraclion SA Auditor Raises 'Going Concern' Doubt CI
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
France's Theraclion Gets US FDA Nod for Clinical Trial of Varicose Veins Treatment MT
Theraclion SA Announces US Food Drug Administration Approve Investigational Device Exemption Application to Initiate the Multi-Center Pivotal Study VEINRESET for the Treatment of Primary Insufficiency of Great Saphenous Veins with SONOVEIN CI
Theraclion Announces Results of First US Trial CI
University of Virginia Cancer Center to Use Theraclion's HD Technology CI
Theraclion SA Announces Last Patient of First Sonovein(R) US Study Has Been Treated CI
Theraclion New Echotherapy for Varicose Veins Partnership with Parisian Region Hospital Wound Center Announced CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Theraclion SA Announces Revenue Result for the First Half of 2022 CI
Theraclion SA Announces the Launch of SONOVEIN® HD CI
France's Theraclion Commences Patient Treatment In Varicose Vein Therapy Study In US MT
Theraclion Announces the Treatment of Varicose Veins Patients with Sonovein for the First Time in the United States CI
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Theraclion Starts First Patient Treatment In Early-Stage Breast Cancer Study MT
Chart Theraclion
More charts
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of equipment (61.8%); - sale of consumables (29%); - provision of after-sales services (9.2%). Export accounts for 99.7% of net sales.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALTHE Stock
  4. News Theraclion
  5. Theraclion : Shares Soar 16% On US FDA Nod For First Vein Therapy Trial